These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 20716140)

  • 21. Preventing end-stage renal disease in diabetic patients - dual blockade of the renin-angiotensin system (Part II).
    Jacobsen PK
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):55-68. PubMed ID: 16470484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Renoprotection and blockade of the renin-angiotensin system: What shall we believe?].
    Kamper AL; Feldt-Rasmussen B; Strandgaard S
    Ugeskr Laeger; 2006 Apr; 168(15):1563. PubMed ID: 16640988
    [No Abstract]   [Full Text] [Related]  

  • 23. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
    Ritz E
    MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423
    [No Abstract]   [Full Text] [Related]  

  • 24. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination treatment and renal function in patients with chronic kidney disease.
    Renke M; Rutkowski P; Tylicki L; Rutkowski B
    J Renin Angiotensin Aldosterone Syst; 2010 Jun; 11(2):146-7. PubMed ID: 20223790
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease.
    Dhaun N; Macintyre IM; Melville V; Lilitkarntakul P; Johnston NR; Goddard J; Webb DJ
    Hypertension; 2009 Sep; 54(3):e19-20. PubMed ID: 19652085
    [No Abstract]   [Full Text] [Related]  

  • 27. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T; Pohl M; Misselwitz J; John U
    Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 30. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment.
    Andersen NH; Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):146-52. PubMed ID: 11881115
    [No Abstract]   [Full Text] [Related]  

  • 32. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New findings with RAS inhibitors in diabetic nephropathy].
    Ito S
    Nihon Jinzo Gakkai Shi; 2007; 49(5):485-90. PubMed ID: 17695809
    [No Abstract]   [Full Text] [Related]  

  • 34. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
    Barnas U; Mayer G
    Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A; Majkowska L
    Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual renin-angiotensin system blockade: on the target.
    Robles NR
    Int J Clin Pract; 2008 Aug; 62(8):1134-6. PubMed ID: 18705817
    [No Abstract]   [Full Text] [Related]  

  • 37. [ACE inhibitors and AT-II antagonists--do they protect against renal disease?].
    Rossing P; Parving HH
    Ugeskr Laeger; 2006 Apr; 168(15):1564; author reply1564-5. PubMed ID: 16640990
    [No Abstract]   [Full Text] [Related]  

  • 38. Aliskiren and dual therapy in type 2 diabetes mellitus.
    Ingelfinger JR
    N Engl J Med; 2008 Jun; 358(23):2503-5. PubMed ID: 18525047
    [No Abstract]   [Full Text] [Related]  

  • 39. [RAS blockade].
    Jin C; Ito S
    Nihon Rinsho; 2004 Oct; 62(10):1880-4. PubMed ID: 15500134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating diabetic nephropathy: unfinished success is not failure.
    Lewis J
    Clin J Am Soc Nephrol; 2007 May; 2(3):407-9. PubMed ID: 17699442
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.